As global health experts gather in Rwanda, two of the big pharma players that have been most active in increasing access to medicines in low-income countries, GSK plc and Novartis AG, have upped their R&D commitments to tackling neglected tropical diseases (NTDs).
GSK And Novartis Double Down On Neglected Disease R&D Spend
Big Pharma Steps Up
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.
More from Anti-infective
More from Antiparasitic
• By
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.
• By
Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.
• By
Chagas is in the spotlight with Novartis, Bayer and DNDi running different trials designed to tackle the neglected tropical parasitic disease.